IL6 and rheumatoid arthritis: Present therapeutic strategies, such as monoclonal antibodies targeting IL-6R (e.g., tocilizumab), have shown great potential in clinical trials of rheumatoid arthritis but are not optimal, as they target global IL-6 signaling and do not discriminate between cis- and trans-signaling; consequently, they can lead to undesirable side effects [8].